Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 in mild Alzheimer's disease
NCT00795418Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2008
- Primary completion
- Nov 2010
- Modality
- Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing CAD106 with Placebo (2 arms). Primary endpoint: Safety and tolerability of repeated injection of CAD106 at 52 weeks. Started Oct 2008; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00795418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795418.